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Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play a critical role in initiating the immune response. They 
develop in peripheral organs and are unique in their 
ability to prime naive T cells.1 As a result, they repre-
sent a particularly attractive cell component for immu-
notherapy.2 Recent advances in the isolation and culture 
of DCs from CD34+ cells make it possible to generate 
ex vivo DCs that are quantitatively suitable for clinical 
trials and retain their function as APCs.3 A potentially 
powerful strategy in cancer gene therapy involves the 
use of genetically engineered DCs with a defined gene 
that results in long-term transgene expression, which is 
the ambition of much research today.4,5 Various strate-
gies (including viral and nonviral approaches) have been 
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BACkgROunD: dendritic cells (dcs) play a critical role in the immune response and are a candidate for im-
munotherapy in cancer. since gibbon ape leukemia virus (GalV) transduction of cd34+ cells is reasonably 
efficacious, we asessed the efficacy of GalV transduction of cd34+ derived dcs as a possible approach to 
creating genetically modified dcs for immunotherapy.
MAtERIALs AnD MEthODs: peripheral blood cd34+ cells were transduced with retroviruses obtained from 
the pG13/ln c8 cell line, with the neomycin gene as a marker gene. after prestimulation of hematopoietic cells 
for 24 hours with 10 ng/ml interleukin (il)-3, 10 ng/ml il-6, 100 ng/ml stem cell factor, 100 ng/ml granulocyte-
macrophage colony stimulating factor and 8 µg/ml protamine sulfate, the cells were cultured in a transforming 
media prior to differentiating into dcs by Gm-csf, tnf-a and il-4. immunophenotyping analyses for confirma-
tion of the generated dcs, colony formation assay and pcr were done for the expression of neomycin gene in 
the transduced cells.
REsuLts: titration of viral vectors indicated a transduction efficiency of 1×105 cfu/ml. transduction efficiency 
for the cd34+ cells transformed to dcs was 45% and 38% before and after dc differentiation, respectively. 
additionally, a mean (sem) of 26.9% (11.4%) and 41.4 (11.8%) of the genetically modified dcs were positive 
for cd86+ hla-dr and cd1a+cd14, respectively
COnCLusIOn: this study showed that the majority of transduced cd34+ cells were successfully differenti-
ated into cells identical to dcs according to morphology and immunophenotyping features, which could be a 
potential application in immunotherapy. 
used to investigate genetically modified DCs.2 Among 
the viral strategies, retrovirus-based vectors have the 
capacity of infecting the dividing cells. Given this, they 
can be employed as transducing agents for CD34+ cells 
because genetic modification in primitive stem cells de-
liver their progeny such as DCs and results in long-term 
expression of antigen.6,7 However, a low transduction ef-
ficacy due to a low titer of virus is the main drawback 
of retroviral transduction.8 Various transduction effica-
cies of CD34+-derived DCs using retroviral vectors 
have been reported in previous studies.8,9 Similarly, it 
has been shown that Moloney murine leukemia virus 
(MoMLV)-based vectors carrying the env protein of 
gibbon ape leukemia virus (GALV) can produce high-
titer retroviral vectors with a wide host range,10 result-
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ing in significant transduction efficacy in primate and 
human cells.11,12 Accordingly, we aimed to evaluate the 
transduction of CD34+-derived DCs by this viral vec-
tor. 
Consequently, owing to the importance of retroviral 
construct as one of the main factors affecting the per-
sistent expression of transgene, and also the promising 
results obtained following the transduction of CD34+ 
cells with GALV produced from TE-FLY MOSALF 
cells and their derivation into DCs,13 we were encour-
aged to examine GALV produced from another pack-
aging cell line, PG13, which showed good efficiency in 
CD34+ cell transduction in previous reports,11 although 
there is no evidence on the efficacy of transmission of the 
defined gene to their cell progenies such as DCs. In addi-
tion, to establish a clinically applicable method, a cell free 
supernatant of the viral vector was used for transduc-
tion. To evaluate transduction and derivation efficacy of 
DCs, gene expression and immunophenotype analysis 
were carried out on the genetically modified DCs.
MAtERIALs AnD MEthODs 
CD34+ cell purification
Apheresis samples (n=5) obtained from donors were 
stimulated with recombinant granulocyte-colony stimu-
lating factor (G-CSF). Mononuclear cells were isolated 
by density gradient centrifugation on Ficoll 1.077 and 
depleted from the adherent cells by 2-hour incubation 
on flat bottom flasks in DMEM +10% FBS medium at 
37ºC in a 5% CO2 atmosphere. The CD34+ cells were 
isolated by positive immunoselection using Dynal mag-
netic bead (GIBCO-BRLGrand Island, NY, USA) and 
their purity was enumerated by flowcytometery using 
phycoerythrin (PE)-conjugated anti CD34+ (R7125 
Dako) monoclonal antibody.
Viral vector preparation and titration on Hela cell line 
PG13/LN C8 cells (ATCC-CRL-10686), which had 
already been cultured in HAT/HT medium and 10-7 
M methotrexate for 5/2/5 days, respectively, were tryp-
sinized and plated at 9×105/60mm dishes (n=6). After 
72 hours, the medium was replaced. It was then aspi-
rated every 12 hours for 3-4 times and filtered through 
0.45 µm filters. This viral condition media (VCM) was 
then used for G418 resistance tittering on Hela cells; 
5×104 cells/well were cultivated in a 6-well culture plate 
in DMEM containing 10% FBS (GIBCO-BRL, Grand 
Island, NY, USA), 1% protamine sulfate (Sigma, St. 
Louis, MO, USA). After 24 hours, they were refed with 
the medium and infected with 100 µL diluted VCM 
(10-1-10-3). The virus-containing medium was aspirat-
ed and the cells were trypsinized. Cell suspension (con-
taining the medium and 500 µg/ml G418 (GIBCO-
BRL, Grand Island, NY, USA) with the dilutions rang-
ing from 1/10 to 1/500 were then prepared. Finally, the 
colonies were counted on each plate by day.10-14 
Gene transduction of CD34+ cells 
Retroviral transduction was performed as follows: 2×105 
CD34+ cells (n=4) were incubated for 24 hours in a 
RetroNectin-coated plate in serum free media supple-
mented with 10 ng/mL IL3, 10 ng/mL IL6, 100 ng/mL 
SCF, 100 ng/mL GM-SCF and 8µg/mL protamine sul-
fate and VCM with the viral titer of 104-105 CFU/mL. 
They were refed after 24 and 72 hours. The cells were 
then harvested from the plates, seeded into new dishes 
and cultivated in liquid culture with GM-CSF (100 
ng/mL), TNF-a (10 ng/mL) and IL-4 (200 U/mL) 
(R&D) in serum free media for DC generation.
Differentiation of CD34+ cells to DCs
The DCs were generated using 2×104 cells/mL (4×104 
cells/well) in the presence of 100 ng/mL GM-CSF 
(R&D), 10 ng/mL TNF-a (R&D), 100 ng/mL SCF 
(R&D) and 200 u/mL IL-4 (R&D) in serum free me-
dia at 37ºC in a 5% CO2 atmosphere. The cultures were 
then split every 4-5 days with medium containing fresh 
growth factors. SCF was added only for the first four 
days. Both cells in supernatant and adherent cells were 
recovered using a 5mM EDTA solution (Sigma, St. 
Louis, MO, USA) and counted on days indicated. 
Enumerating immunophenotype of the generated DCs 
The immunophenotypes were identified by flowcytom-
etry analysis using monoclonal antibodies conjugated to 
PE or FITC:CD1_-FITC (Dako F7141), CD14-PE 
(Dako R0864), CD3-FITC (Dako F0818), CD19-FITC 
(Dako F0768), CD86-FITC (Dako F7205),CD56-PE 
(Dako R7251), HLA-DR-FITC and PE (DakoR7267 
and F7266 ) (Dako, Denmark). After incubation with 
2% mouse serum at 4ºC, the cells were incubated with 
conjugated monoclonal antibodies for 30 minutes at 4ºC 
at a final concentration of 106 cells resuspended in PBS 
1X per each reaction and analysed by flowcytometer. 
G418-resistance colony formation assay 
To assess G418 resistance of the neomycin gene-trans-
duced cells, colony formation assay was performed. The 
transduced and non-transduced CD34+ cells and de-
rived DCs were cultivated in DMEM containing 10% 
FBS, 1% protamine sulfate and 500 µg/mL G418. After 
14 days of cultivation, colony formation was evaluated 
by microscopic and PCR analyses.
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PCR analysis for the expression of neomycin gene 
To ascertain whether the transduced cells expressed the 
neomycin gene, DNA was extracted following the stan-
dard procedures from equal numbers of infected and 
mock-infected cells. The extracted DNA was amplified 
in a 25 µL reaction with the primers specific for STR 
or the neomycin gene in an Eppendorf Mastercycler 
gradient. The sequences of the primers were as follows: 
(STR F) GATCCCAAGCTCTTCCTCTT-3’, (STR 
R) 5’-ACGTTTGTGTGTGCATCTGT-3’, (neo F) 
5’-CTGAAGCGGGAAGGGACT-3’ and (neo R) 5’-
GGCCACAGTCGATGAATC-3’. The amplification 
profiles were 1 minutes 94ºC, 1 minutes 55ºC and 1 
minute 72ºC for 40 cycles. The expected size of the am-
plified products -neo and STR- was 359 bp and 14 bp 
for STR, respectively. Amplified products were analyzed 
in a 2% agarose gel run in TBE buffer and stained with 
ethidium bromide.
REsuLts
Determination of multiplicity of infection of VCM on 
Hela cells 
Hela cells were used for the detection of VCM titer in 
a G418 containing media. After plating of Hela cells for 
24 hours, they were infected by VCM. 24 hours later, 
they were trypsinized and the cell suspension was di-
luted from 1/10 to 1/500. The concentration of 500 µg/
mL G418 (GIBCO) was used to select the transduced 
cells. Then, the produced colonies were counted on each 
plate by day.10-14 The results indicated that multiplicity of 
infection was: 1.0×105 CFU/mL (Figure 1). 
Retroviral transduction of CD34+ cells and expression 
in DCs
 Retroviral transduction of the CD34+ cell population 
was done by culturing of the prestimulated CD34+ cells 
in a serum free media containing SCF, GM-CSF, IL-3 
and IL-6 in the presence of VCM. Refeeding was done 
by fresh media after 24 and 72 hours. Then, TNF-a was 
added by day 4. The generation of DCs was estimated 
by analyzing the morphology and phenotype of the cell 
populations. 
Derivation of CD34+ cells to DCs
The purified CD34+ cells (often more than 90%) were 
cultured for up to 10 days in the serum free media con-
taining SCF, GM-CSF, TNF-a and IL4. As a result, 
the total cell number, including the adherent and non-
adherent cells were considerably increased. On day 10, 
a heterogeneous cell population was observed, which 
included non-adherent cells with round morphology 
Figure 1. Colony formation assay for determining viral titration on Hela cells. Hela cells 
plated for 24hrs, then transduced by vCm; 24 hours later Hela cells were trypsinized 
and selection of transduced cells was done by 500 µg/ml g418. after 14 days, produced 
colonies were counted and viral titration was 1.0×105 CFU/ml.
Figure 2. Derived dendritic cells following CD34 transduction. after transduction of 
CD34+ cells by galv vector, they were cultivated in a serum free media containing 
SCF, gm-CSF, TnF-a and il4 for 10 days. Flat macrophage-like cells were observed in 
microscopic analysis.
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or cytoplasmic spikes peculiar to DCs along with a 
monolayer of large adherent flat macrophage-like cells 
(Figure 2). 
Immunophenotypic analysis of the generated DCs
As can be seen in (Figure 3), flowcytometric analysis of 
cell surface markers of the derived DCs revealed lack 
of CD3, CD19 and CD56 expression on the generat-
ed DCs. Also, we found that 26.9% (11.4) and 41.4% 
(11.8) of the genetically modified DCs were positive for 
CD86+ HLA-DR and CD1a+CD14, respectively.
Colony formation assay for the transduced G418-re-
sistance gene
For determining G418 resistance of the neomycin gene 
transduced cells, colony assay was performed. The trans-
duced CD34+ cells in DMEM containing 10% FBS, 
1% protamine sulfate and 500mg/mL G418 survived 
well, while the control CD34+ cells viability declined 
an much as 90% after a week. Similarly, the transduced 
derived DCs tolerated the medium well, while CD34+ 
control cell derived DCs were entirely destroyed. 
PCR results
To verify the genetic transfer of the neomycin gene in 
CD34+ cells and their derived DCs, PCR analysis was 
done for detecting Neomycine gene in addition to STR, 
as internal control.
As can be seen in (Fig 4A and B), our findings in-
dicated that 45% to 49% of CD34+ cells and 29% to 
38% of DCs were positive for this selectable marker, 
Neomycine, in agarose and polyachrylamide gel electro-
phoreses. 
DIsCussIOn
Transduction of DCs, which is a key approach for the 
induction of immune responses (including antitumoral 
responses), is currently considered a promising strategy 
for cellular immunotherapy.14 The potential of ex vivo 
generation of DCs enables the development of genetic 
modification for stimulating immune responses against 
the desired antigen. Additionally, retroviral transduc-
tion enables gene transduction into the stem cells and 
consequently, into their progenies such as DCs.15,16 
However, this optimism is hampered by some limita-
tions, such as low transduction efficacy in the genetic 
modification of DCs.2
 Accordingly, we aimed to optimize the retroviral 
transduction of CD34-derived DCs, using the GALV 
vector. For this purpose, mPBCD34+ cells were used 
as target cells, cultured in serum-free medium (con-
taining a defined cytokine cocktail) and transduced on 
Figure 3. Flowcytometery analysis of genetically modified derived 
DCs. CD34+ derived DCs generated in ex vivo, were harvested 
and analyzed for detection of DCs markers. The absence of CD3, 
CD19, CD56 expression and the presence of CD86+ Hla-Dr and 
CD1a+CD14, revealed that DCs were generated following CD34 
transduction.
Figure 4. PCr analysis 
of the neomycin 
gene in CD34+ cells. 
(a) before and 
after differentiation 
of CD34+ cells to 
DCs their Dna was 
extracted and PCr 
analysis was done. 
amplified products 
were run by agarose 
gel electrophoresis 
(CD34+= 45%, DCs 
=38%). left to right: 
ladder-size marker, 
negative control, 
transduced CD34+ 
cells, CD34+ derived 
DCs, positive control. (b) PCr detection of neomycin gene 
after transduction to CD34+ cell and differentiation to DCs in 
polyacryleamd gel (first and second column: DCs=29% [internal 
control: 34.2, 36.6], 7.3% [internal control: 46.4, 46.1]-third and 
fourth column: CD34+= 49.9% [internal control: 25.8, 24.2], 32.3% 
[internal control: 34.2, 33.4]) 
AA
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CH296-coated plates preloaded with VCM. Further, in 
the present study, we used retronectins, an extracellular 
matrix protein, and protamin sulfate for improving the 
transduction efficacy.17,18
The results of viral vector titration on Hela cells 
gave a reasonable infective titer for CD34+ transduc-
tion compared with the results obtained by previous 
reports; 5×105 19 and 7×105.12 Higher titers obtained 
in other studies are the results of different methods of 
vector preparation, mostly using ultracentrifugation for 
concentrating the supernatants containing the viral vec-
tor. However, so that maximal biological activity of the 
viral vector could be preserved, we did not concentrate 
the supernatant. 
We then determined the immunophenotype of the 
generated transduced DCs by flowcytometry. The re-
sults showed that the expression of CD86+ HLA-
DR and CD1a+CD14 was positive among the gener-
ated DCs. For evaluating the transduction efficacy of 
CD34- derived DCs, PCR analysis was carried out. 
The results showed that a large proportion (45%-
49%) of CD34+ cells that were transduced by GALV 
expressed the neomycin gene. Also, 29%-38% of the 
generated DCs, following CD34+ cells differentiation, 
represented the neomycin gene, as well. Furthermore, 
the existence of a G418-resistance colony in the trans-
duced CD34+ and DCs confirmed the PCR results. 
The diverse range of transduction efficacy obtained in 
the previous reports ranged from 11.5% to 86%. For 
example, the average transduction efficiency for the 
cord blood and bone marrow CD34+-derived DCs 
was about 10% to 20%.8 Heemskerk et al reported 
40%-60% cell transduction following amphotropic 
retroviral transduction.9 Using GALV produced by 
TE-FLY MOSALF cells13 it has been shown that 
more than 70% of DCs derived from cord blood or 
mobilized progenitors have been transduced. Various 
sources of DCs, vectors and methods of transduction 
resulted in these differences.20
The higher efficiency observed in some experiments 
seems to be mainly due to cocultivation on viral vec-
tor producer cells, which is not desirable in clinical ap-
proaches8 or following the combination of centrifugal 
and liposomal methods.13 In the transduction process, 
however, owing to the maintenance of maximum bio-
logical activity of the viral vector, viral concentration 
was not performed in our experiment.
One of the main advantages of our experiment is 
the use of a modified version of the amphotropic ret-
roviral vectors. Its envelope has been replaced by the 
GALV env gene and produced by packaging the cell 
line, PG13, resulting in tropism for a wide range of 
cell types and higher viral titers.12 Also, its receptors on 
human mPBCD34+ cells have been shown previous-
ly.12 Therefore, optimization of this viral vector source 
for genetic modification will be achievable, which was 
preliminarily assessed in the present study. Although 
we did not reach a high transduction efficiency, espe-
cially in the genetically modified DCs, we believe that 
additional optimization, especially in the transduction 
procedure of CD34+ cells and their derivation into 
DCs, will be beneficial.
In conclusion, as a result of DC resistance to ret-
roviral transduction, we attempted GALV transduc-
tion of CD34+ cells for genetic manipulation of DCs 
GALV transduction might substitute for other vec-
tors, which have been unsuccessful. However, further 
studies are required to optimize this GALV vector to 
improve gene transduction efficacy, and to improve the 
functional behavior of the genetically modified DCs.
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